A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8+ cytotoxic T lymphocytes

International Journal of Cancer

Volumn 87, Issue 4, 2000, Pages 553-558

  Ikuta, Yasushi ^a,b   Okugawa, Toshiharu ^a   Furugen, Reiko ^b   Nagata, Yasuhiro ^b   Takahashi, Yoshiyuki ^a   Wang, Lijie ^a   Ikeda, Hiroaki ^a   Watanabe, Masato ^a   Imai, Shigemi ^c   Shiku, Hiroshi ^a  

^a MIE UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c Japanese Red Cross Society   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; HLA A2 ANTIGEN; TUMOR REJECTION ANTIGEN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HLA SYSTEM; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR REJECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; ANTIGENS, CD3; ANTIGENS, CD8; ANTIGENS, NEOPLASM; CANCER VACCINES; CLONE CELLS; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HLA-A ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; MICE; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0033882792     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20000815)87:4<553::AID-IJC15>3.0.CO;2-8     Document Type: Article

References (39)

1. A novel ex vivo method for assaying adhesion of cancer cells to the peritoneum
2. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
3. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity
4. DNA typing of the HLA-A gene: Population study and identification of four new alleles in Japanese
5. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
6. In vitro generation of human cytolytic T-cell specific for peptides derived from the HER-2/neu protooncogene protein
7. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
8. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
9. The c-erbB-2 proto-oncogene in human pancreatic cancer
10. Evolution of the proteasome components
11. Mutated MAP kinase. A tumor rejection antigen of mouse sarcoma
12. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
13. Granulocytemacrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
14. HLA-B51 transgenic mice as recipients for production of polymorphic HLA-A, B-specific antibodies
15. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells
16. p185(neu) expression in human lung adenocarcinomas predicts shortened survival
17. Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer
18. Identification of HER2/neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8
19. Peptide motifs of HLA-A3, -A24, and -B7 molecules as determined by pool sequencing
20. Comparison of seven cell lines derived from human gastric carcinomas
21. Definition of a unique cell surface antigen of mouse leukemia RL male 1 by cell-mediated cytotoxicity
22. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts
23. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2)
24. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide
25. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells
26. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
27. Evolution and developmental regulation of the major histocompatibility complex
28. Impaired assembly and transport of HLA-A and -B antigens in a mutant TXB cell hybrid
29. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin 4 and down regulated by tumor necrosis factor alpha
30. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
31. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
32. NK susceptibility varies inversely with target cell class I HLA antigen expression
33. Variable expression on lung cancer cell lines of HLA-A2-binding MAGE-3 peptide recognized by cytotoxic T lymphocytes
34. The MHC class I ligand-generating system: Roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28
35. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma
36. T cell defined tumor antigens
37. Selection of highly transfectable variant from mouse mastcytoma P815
38. Expression of the neu gene encoded protein (p185(neu)) in human non-small cell carcinomas of the lung
39. + dendritic cells